Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.46
+0.55781.75%
Post-market: 32.460.00000.00%19:30 EDT
Volume:2K
Turnover:49.64K
Market Cap:41.39M
PE:- -
High:32.46
Open:32.27
Low:32.24
Close:31.90
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.40
T/O Rate:0.12%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

TIPRANKS
·
Sep 28

Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

EBR Systems advances FDA approval process for new WiSE manufacturing site

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Legend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and Alive

MT Newswires Live
·
Sep 25

Legend Biotech Reports Five-Year CARVYKTI Survival Data in Earlier-Line Myeloma

TIPRANKS
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

Health Rounds: Genetic Discovery Yields Clues Toward Reversal of Alzheimer's Brain Damage

Reuters
·
Sep 25

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Moderna Inc. Stock Advances 7.0%, Outperforms Peers

Dow Jones
·
Sep 25

Legend Biotech Shareholders Back Board Slate and Expand Equity Plan at 2026 AGM

TIPRANKS
·
Sep 25

Legend Biotech Shareholders Voted at Annual General Meeting

Reuters
·
Sep 25

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 25